Muscle matters: a review of diagnostic methods in sarcopenia

Abstract

Background

Sarcopenia is characterized by the progressive loss of muscle mass and strength, associated with increased risk of fractures, frailty, morbidity, and mortality. Despite being a preventable and potentially reversible condition, its diagnosis remains challenging due to variability in diagnostic criteria and methods. The Global Leadership Initiative in Sarcopenia recommends including both muscle mass and strength in the diagnostic definition of sarcopenia. This review aims to explore different diagnostic approaches for sarcopenia, focusing on their accuracy, feasibility, clinical utility, and existing limitations.

Methods

A narrative review was conducted using PubMed to identify studies on sarcopenia diagnosis and assessment. Articles were selected based on relevance to muscle strength, muscle mass, and physical performance, with predefined inclusion and exclusion criteria. Consensus guidelines from major international working groups were also included.

Key findings

Assessment of muscle mass in sarcopenia is constrained by a fundamental imbalance between measurement accuracy and clinical feasibility. In clinical settings, dual-energy X-ray absorptiometry and bioelectrical impedance analysis remain at the forefront of muscle mass evaluation despite the limitation of being indirect methods. Muscle ultrasound is emerging as a promising method for the future and can be used adjunctly to evaluate muscle architecture. Cross-sectional direct imaging techniques such as CT and MRI can be used opportunistically as they provide high accuracy but lower feasibility. D3-creatine dilution is emerging as an accurate assessment tool for the future but requires further research into clinical implementation. Overall, assessment of muscle strength and muscle mass remains central to the diagnosis of sarcopenia, while physical performance measures are important for outcome prediction.

Conclusion

No single diagnostic method is sufficient on its own, and substantial heterogeneity remains in sarcopenia assessment. A pragmatic approach combining measures of muscle strength, muscle mass, and physical performance is therefore required.